Keros Doses First Patient in Phase 2 DMD Trial, Confirming Operational Milestone

What happened

Keros Therapeutics announced on September 28, 2026, that the first patient was dosed in the Phase 2 trial of rinvatercept (KER-065) in Duchenne muscular dystrophy. The DeepValue report had identified the lack of confirmed Phase 2 initiation and absence of a ClinicalTrials.gov record as a critical operational risk, with a target confirmation by mid-2026. This news provides the long-awaited confirmation, though it arrives roughly three months later than the company's earlier guidance of Q1 2026. The stock had traded down to $13.40 in early March 2026 from a high of $21.69 in December 2025, reflecting investor uncertainty over the timeline. While the press release validates the program's advancement, it lacks details on trial design, site activation count, or expected enrollment, leaving some transparency gaps that the market has been monitoring.

Implication

Investors should treat this as a positive but incomplete de-risking event. The first patient dosed in the DMD trial resolves the binary question of whether Keros could initiate the study, but the three-month delay versus prior guidance suggests operational friction that may persist into enrollment. The absence of a ClinicalTrials.gov record in the press release is notable; the market will likely demand trial registry visibility and initial site count to validate readiness. With cash of $693.5 million as of September 2025 and partner-funded elritercept development, downside remains cushioned, but the stock's re-rating will depend on demonstrated enrollment pace and upcoming safety data in DMD patients. Until those signals emerge, KROS may trade closer to the $12.50 attractive entry level from the DeepValue report rather than the $16.00 base case.

Thesis delta

The investment thesis hinged on confirmation of KER-065 Phase 2 initiation by mid-2026; today's announcement satisfies that prerequisite, albeit three months late. The delay lowers the probability of near-term multiple expansion but shifts the key risk from 'will the trial start?' to 'can the company enroll efficiently and produce interpretable signals?' The balance-sheet support and partner economics remain intact, but market confidence will not fully recover until Keros provides trial registration details and initial site activation numbers.